Aimmune Therapeutics’ (AIMT) Buy Rating Reiterated at Wedbush

Aimmune Therapeutics (NASDAQ:AIMT)‘s stock had its “buy” rating reiterated by stock analysts at Wedbush in a note issued to investors on Thursday, AnalystRatings.com reports. They presently have a $79.00 target price on the biotechnology company’s stock. Wedbush’s price target would suggest a potential upside of 285.18% from the company’s current price.

A number of other analysts also recently commented on the company. BidaskClub downgraded Aimmune Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, January 25th. Zacks Investment Research upgraded Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, January 29th. Credit Suisse Group restated a “buy” rating and issued a $40.00 target price on shares of Aimmune Therapeutics in a research note on Tuesday, January 15th. Finally, ValuEngine downgraded Aimmune Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, February 4th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company’s stock. Aimmune Therapeutics presently has an average rating of “Hold” and a consensus target price of $49.00.

Aimmune Therapeutics stock opened at $20.51 on Thursday. The stock has a market cap of $1.28 billion, a price-to-earnings ratio of -5.59 and a beta of -0.20. Aimmune Therapeutics has a fifty-two week low of $19.25 and a fifty-two week high of $36.12.

Aimmune Therapeutics (NASDAQ:AIMT) last posted its quarterly earnings results on Thursday, February 28th. The biotechnology company reported ($0.95) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.84) by ($0.11). As a group, equities research analysts forecast that Aimmune Therapeutics will post -3.95 earnings per share for the current year.

Several institutional investors and hedge funds have recently modified their holdings of the company. Principal Financial Group Inc. boosted its stake in shares of Aimmune Therapeutics by 6.8% during the 1st quarter. Principal Financial Group Inc. now owns 8,962 shares of the biotechnology company’s stock worth $200,000 after acquiring an additional 570 shares in the last quarter. Botty Investors LLC acquired a new position in shares of Aimmune Therapeutics during the 1st quarter worth approximately $2,505,000. Swiss National Bank raised its position in shares of Aimmune Therapeutics by 9.2% during the 1st quarter. Swiss National Bank now owns 73,374 shares of the biotechnology company’s stock worth $1,640,000 after purchasing an additional 6,200 shares during the last quarter. Fiera Capital Corp raised its position in shares of Aimmune Therapeutics by 80.3% during the 1st quarter. Fiera Capital Corp now owns 160,572 shares of the biotechnology company’s stock worth $3,589,000 after purchasing an additional 71,519 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale raised its position in shares of Aimmune Therapeutics by 21.8% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 15,100 shares of the biotechnology company’s stock worth $423,000 after purchasing an additional 2,700 shares during the last quarter. Hedge funds and other institutional investors own 73.66% of the company’s stock.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.

Further Reading: How to Profit and Limit Losses With Stop Orders

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.